Page last updated: 2024-11-08

difructose anhydride iii

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

difructose anhydride III: a non-reducing derivative of inulobiose [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID196181
CHEBI ID192285
SCHEMBL ID17931797
MeSH IDM0232384

Synonyms (12)

Synonym
difructose anhydride iii
CHEBI:192285
alpha-d-fructofuranose-beta-d-fructofuranose 2',1:2,3'-dianhydride
(2r,3's,4's,4ar,5'r,6r,7r,7as)-4a,5',6-tris(hydroxymethyl)spiro[3,6,7,7a-tetrahydrofuro[2,3-b][1,4]dioxine-2,2'-oxolane]-3',4',7-triol
81129-73-9
beta-2,1'-alpha-2',3-difructofuranose anhydride
SCHEMBL17931797
9f3 ,
]-3',4',7-triol
(2r,3's,4's,4ar,5'r,6r,7r,7as)-4a,5',6-tris(hydroxymethyl)spiro[3,6,7,7a-tetrahydrofuro[2,3-b][1,4]dioxine-2,2'-oxolane
dfa iii; difructose iii; twintose
(2r,3s,4s,4a'r,5r,6'r,7'r,7a's)-4a',5,6'-tris(hydroxymethyl)hexahydro-3h,3'h-spiro[furan-2,2'-furo[2,3-b][1,4]dioxine]-3,4,7'-triol

Research Excerpts

Overview

Difructose anhydride III (DFAIII) is an indigestible disaccharide. It has been shown to enhance iron absorption in animal studies. However, the effect has not been investigated in anemic subjects.

ExcerptReferenceRelevance
"Difructose anhydride III (DFAIII) is a prebiotic involved in the reduction of secondary bile acids (BAs). "( Ingestion of difructose anhydride III partially suppresses the deconjugation and 7α-dehydroxylation of bile acids in rats fed with a cholic acid-supplemented diet.
Fukiya, S; Hori, S; Ishizuka, S; Kitta, S; Kohmoto, O; Lee, DG; Nagura, T; Shimizu, H; Takahashi, K; Tanaka, Y; Uchino, H; Yokota, A; Yoshida, R, 2019
)
2.33
"Difructose anhydride III (DFAIII) is an indigestible disaccharide and has been shown to enhance iron absorption in animal studies; however, the effect has not been investigated in anemic subjects. "( Difructose anhydride III enhances bioavailability of water-insoluble iron in anemic Vietnamese women.
Dung, NT; Hien, VT; Khan, NC; Kise, M; Lam, NT; Nakamori, M; Okuhara, Y; Shigematsu, N; Shiomi, T; Uotsu, N; Yamamoto, S, 2010
)
3.25
"Difructose anhydride III (DFAIII) is a newly manufactured non-digestible disaccharide with unique fermentation properties."( Supplementation of difructose anhydride III enhanced elevation of plasma equol concentrations and lowered plasma total cholesterol in isoflavone-fed rats.
Hara, H; Nishimukai, M; Shigematsu, N; Tamura, A, 2006
)
1.38

Bioavailability

ExcerptReferenceRelevance
" In Experiment 2, we demonstrated that Ca absorption rate in sham and OVX rats fed a diet containing 3% DFAIII was higher than that in rats fed a DFAIII-free diet 4 wk after consuming the test diets."( Supplemental feeding of difructose anhydride III restores calcium absorption impaired by ovariectomy in rats.
Aoyama, Y; Chiji, H; Hara, H; Mitamura, R, 2002
)
0.62
" Recovery of Ca absorption rate by DFAIII was greater in the OVX than in the sham showing an interaction between OVX and VD deficiency in, at least, the DFAIII-fed groups."( Ingestion of difructose anhydride III partially restores calcium absorption impaired by vitamin D and estrogen deficiency in rats.
Hara, H; Mitamura, R, 2006
)
0.7
" The apparent calcium absorption (mg/d) and rate of absorption (%) were higher, and those of retention were much higher, in the DFAIII group than in the control group."( Ingestion of difructose anhydride III enhances absorption and retention of calcium in healthy men.
Hara, H; Okuhara, Y; Shigematsu, N; Shiomi, T; Tamura, A; Tomita, K, 2007
)
0.71
" The absorption rate of calcium, but not of iron, from the jejunal loops was increased by the addition of DFAIII (100 mmol/L)."( Difructose anhydride III promotes iron absorption in the rat large intestine.
Hara, H; Nakagawa, C; Onoshima, S, 2010
)
1.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sugar dianhydrideCyclic products of condensation of two monosaccharide molecules with the elimination of two molecules of water.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (3.57)18.2507
2000's28 (50.00)29.6817
2010's25 (44.64)24.3611
2020's1 (1.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.09 (24.57)
Research Supply Index4.11 (2.92)
Research Growth Index5.40 (4.65)
Search Engine Demand Index25.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (5.26%)5.53%
Reviews5 (8.77%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (85.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]